Project Grant R44AA030231

Award Date 9/1/22
Completion Date 4/30/26
Dollars Obligated $8.1M
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, provides $385,000 in funding to Soovu Labs Inc. to develop a wearable medical device to treat anxiety and stress in individuals with alcohol use disorder (AUD). The funding will support a two-phase project. Phase I will determine the optimal stimulation parameters for activating C-tactile (CT) fibers and thermally-sensitive...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), aims to examine transdermal alcohol concentration (TAC) features as predictors of alcohol-related consequences and alcohol use disorders (AUD) among young adults. The $613,777 grant will fund a large-scale, 2-year longitudinal study involving 500 participants aged 19-22 who frequently engage in heavy episodic drinking. The study will utilize a...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, provides $1,373,036 to Yale University to enhance the understanding and prediction of heavy drinking episodes during initial recovery from alcohol use disorder (AUD). The key objectives are to: 1) Develop real-time predictive models using wearable sensor data to accurately forecast heavy drinking episodes during initial AUD...
This federal Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to demonstrate the feasibility of developing a rapid point-of-care phosphatidylethanol (PEth) lateral flow immunoassay for monitoring alcohol consumption. The $399,293 award was granted to Echelon Biosciences Inc., a for-profit manufacturer of biochemical reagents and assays, to partner with an expert at Brigham Young University to...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program will fund a prospective study to utilize smartwatch-based sensing to identify biopsychosocial predictors of binge drinking onset in first-year college students. The $105,057 award to Temple University will support a 22-month study of 100 incoming college freshmen without prior binge drinking or alcohol use disorder histories. The...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $643,948 to Labsys LLC, a for-profit limited liability company, to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The device is designed as a low-cost, painless patch that can monitor medication levels in the interstitial fluid, providing real-time insights into the effectiveness of opioid use...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $999,393 Cooperative Agreement under the Alcohol Research Programs (CFDA 93.273) to Stress Therapeutics, Inc. on May 15, 2025. The purpose of this Phase I SBIR grant is to initiate investigational new drug (IND)-enabling studies for an innovative first-in-class therapeutic candidate aimed at chronic management of pathological hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis for the treatment of alcohol use...
This Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to examine the relationship between transdermal alcohol concentration (TAC) features, alcohol-induced blackouts (AIBs), and other harmful alcohol-related consequences in young adults. The total award amount is $516,146.00, with a project period from September 25, 2024, to August 31, 2026. The key objectives are to: 1) determine whether and...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $645,594 to Ricovr Healthcare Inc. to develop a point-of-need (PON) device called XALIVA for accurate and destigmatized detection of recent cannabis use. The overall goal is to create an effective and scalable monitoring device to decouple the stigma associated with cannabis use disorder and cannabis consumption, while enhancing public safety. The...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...

DISCREET WEARABLE DEVICE FOR CONTINUOUS REAL-TIME MONITORING OF ALCOHOL - ABSTRACT EXCESSIVE ALCOHOL USE REMAINS A LEADING PREVENTABLE CAUSE OF DEATH AND DISABILITY IN THE UNITED STATES. ACCORDING TO THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), AN AVERAGE OF 95,158 ALCOHOL-ATTRIBUTABLE DEATHS (261 DEATHS PER DAY) IS REPORTED ONLY IN THE UNITED STATES, WITH ASSOCIATED ANNUAL COSTS OF $249 BILLION. THE GOAL OF THIS PROJECT IS TO DEVELOP A WEARABLE INTEGRATED DEVICE CAPABLE OF CONTINUOUSLY MEASURING, RECORDING, AND STORING ISF ALCOHOL LEVELS IN REAL-TIME WITHOUT THE NEED FOR EXTERNAL CALIBRATIONS. THE NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA) SEEKS A WEARABLE ALCOHOL MONITORING DEVICE THAT CAN CONTINUOUSLY MEASURE REAL-TIME ALCOHOL LEVELS IN THE BLOOD OR INTERSTITIAL FLUID (ISF), AND THIS PROPOSAL IS HIGHLY ALIGNED WITH THE NIAAA'S MISSION. AN ACCURATE WEARABLE ALCOHOL SENSOR WILL SERVE USEFUL PURPOSES IN DIFFERENT SETTINGS, INCLUDING RESEARCH PROGRAMS, CLINICS, FORENSIC APPLICATIONS, AND CONSUMER USE TO PROMOTE RESPONSIBLE ALCOHOL CONSUMPTION. THE AVAILABLE TRANSDERMAL ALCOHOL MONITORING DEVICES, RELYING ON ALCOHOL DETECTION IN SWEAT OR SWEAT VAPOR, FACE SIGNIFICANT PROBLEMS SUCH AS LONG LAG TIMES (UP TO SEVERAL HOURS) AND TEND TO BE CUMBERSOME. IN THIS CONTEXT, ACTIOX, LLC HAS DEVELOPED A NON-OBTRUSIVE WEARABLE SENSOR PLATFORM TO ENABLE PAIN-FREE ANALYSIS FEW HUNDRED MICRONS UNDER THE SKIN, DIRECTLY IN THE ISF. THE NOVEL SENSING TECHNOLOGY RELIES ON A BIOCOMPATIBLE ARRAY OF MICRONEEDLES, OPTIMIZED FOR PAINLESS SKIN PENETRATION, AND THUS TO PROVIDE CONTINUOUS ACCESS TO CONSTANTLY REVITALIZING ISF. THIS FULLY INTEGRATED WIRELESSLY OPERATED DEVICE IS COMPOSED OF TWO COMPONENTS OF A REUSABLE ELECTRONICS AND A DISPOSABLE MICRONEEDLE ARRAY, ALONG WITH A SUCCESSFUL DEMONSTRATION OF A CUSTOM- DESIGNED APP FOR DATA CAPTURE AND VISUALIZATION. OUR PRELIMINARY DATA USING THE PROTOTYPE DEVICE SHOWED SUCCESSFUL REAL-TIME TRACKING OF ISF ALCOHOL IN RESPONSE TO ALCOHOL DRINKING EPISODES IN MULTIPLE HUMAN SUBJECTS, WITH THE RESULTS WELL CORRELATED TO THOSE FROM A BREATHALYZER. THIS SBIR FAST-TRACK PROJECT WILL LEVERAGE THIS INNOVATIVE TECHNOLOGY TO DEVELOP A DISCREET, REAL-TIME, CONTINUOUS, AND CALIBRATION-FREE CONTINUOUS ALCOHOL MONITORING DEVICE TOWARD PROLONGED ON-BODY OPERATIONS TO ENABLE MORE COMPREHENSIVE AND ACCURATE CLINICAL STUDIES AND ALLOW EFFICIENT CONTROL AND MANAGEMENT OF ALCOHOL-RELATED PROBLEMS, INCLUDING ALCOHOL USE DISORDER. PHASE I CONSTITUTES IN-VITRO FEASIBILITY STUDIES TO FIND THE BEST CHEMICAL MODIFICATION STRATEGY WITH OPTIMAL SENSITIVITY, SELECTIVITY, REPRODUCIBILITY, AND EXTENDED 3-DAYS STABILITY. WE AIM IN PHASE II TO EXECUTE A SERIES OF CLINICAL STUDIES TO DEVELOP A PROSPECTIVE CALIBRATION ALGORITHM THAT CAN CONVERT, IN REAL TIME, THE RAW ELECTROCHEMICAL SENSOR SIGNALS TO BAC. THE DATA GATHERED THROUGH THIS WORK WILL SUPPORT FDA CLEARANCE, AND SUBSEQUENTLY, THE COMMERCIALIZATION OF OUR REAL-TIME, CONTINUOUS ALCOHOL MONITORING WEARABLE SYSTEM AS A RELIABLE AND ACCURATE DEVICE READY TO BE USED BY END USERS, INCLUDING HOSPITALS, DRUG REHABILITATION CENTERS, DRUG TESTING LABORATORIES, GOVERNMENT DEPARTMENTS, AND OTHERS.

Posted 8/30/22, 12:00 AM